脓毒症的表观遗传学
本文为叙述性综述,通过Pubmed检索表观遗传学与脓毒症、感染、危重症、急性呼吸窘迫综合征、急性肺损伤等组合文献,并追溯参考文献。综述体外研究、动物实验及少量人类脓毒症研究显示:感染早期宿主-病原体互作导致宿主细胞表观遗传改变利于病原存活;宿主炎症反应涉及肿瘤坏死因子和白细胞介素-1β等关键基因的表观遗传修饰;人类脓毒症早期多种表观遗传修饰酶表达差异;脓毒症后期表观遗传修饰伴随内毒素耐受和免疫抑制状态;动物模型中表观遗传修饰剂可减轻脓毒症效应、改善生存并逆转脓毒症相关器官损伤。表观遗传标志物在脓毒症诊断和预后方面有前景,修饰剂在动物模型中显示治疗潜力,但该领域人体研究严重缺乏,应成为脓毒症研究者的优先方向。
要点
- 感染起始时宿主-病原体互作常导致宿主细胞表观遗传改变,有利于病原体存活。
- 宿主炎症反应以关键调控基因(包括肿瘤坏死因子和白细胞介素-1β)的表观遗传修饰为特征。
- 人类脓毒症患者早期多种表观遗传修饰酶表达差异,提示表观遗传学参与协调感染应答。
- 脓毒症后期表观遗传修饰伴随内毒素耐受和免疫抑制状态。
- 动物模型中表观遗传修饰剂可减轻脓毒症效应、改善生存并逆转脓毒症相关器官损伤;人体研究严重缺乏。
适用人群与场景
- 脓毒症患者,涵盖早期(感染起始、急性炎症)与后期(内毒素耐受、免疫抑制)阶段。
- 体外研究、动物模型及现有少量人类脓毒症研究。
研究设计与关键结果
- 叙述性综述:通过Pubmed以表观遗传学分别与脓毒症、感染、细菌感染、病毒感染、危重症、急性呼吸窘迫综合征、急性肺损伤组合检索,并追溯参考文献补充文献。
- 体外与动物研究显示:感染起始时宿主-病原体互作导致宿主细胞表观遗传改变,利于病原体存活。
- 宿主炎症反应以肿瘤坏死因子和白细胞介素-1β等关键调控基因的表观遗传修饰为特征。
- 人类脓毒症患者早期多种表观遗传修饰酶表达差异,提示表观遗传学协调感染应答。
- 脓毒症后期表观遗传修饰伴随内毒素耐受和免疫抑制状态。
- 动物模型中表观遗传修饰剂治疗可减轻脓毒症效应、改善生存并逆转脓毒症相关器官损伤。
证据类型、等级与局限
- 证据类型:叙述性综述,汇总体外研究、动物实验及现有少量人类脓毒症研究。
- 局限:人类表观遗传学领域研究严重缺乏,应成为脓毒症研究者的优先方向。
对床旁实践的改变
- 表观遗传标志物在脓毒症诊断和预后方面显示前景。
- 表观遗传修饰剂在动物脓毒症模型中显示治疗潜力,可减轻脓毒症效应、改善生存并逆转脓毒症相关器官损伤。
- 人类表观遗传学研究严重缺乏,应成为脓毒症研究者的优先方向。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Recent evidence from the fields of microbiology and immunology, as well as a small number of human sepsis studies, suggest that epigenetic regulation may play a central role in the pathogenesis of sepsis. The term "epigenetics" refers to regulatory mechanisms that control gene expression but are not related to changes in DNA sequence. These include DNA methylation, histone modifications, and regulation of transcription via non-coding RNAs. Epigenetic modifications, occurring in response to external stressors, lead to changes in gene expression, and thus lie at the intersection between genetics and the environment. In this review, we examine data from in vitro studies, animal studies, and the existing human sepsis studies in epigenetics to demonstrate that epigenetic mechanisms are likely central to the pathogenesis of sepsis and that epigenetic therapies may have potential in the treatment of sepsis and its associated organ failures.
DATA SOURCES: Online search of published scientific literature via Pubmed using the term "epigenetics" in combination with the terms "sepsis", "infection", "bacterial infection", "viral infection", "critical illness", "acute respiratory distress syndrome", and "acute lung injury".
STUDY SELECTION: Articles were chosen for inclusion based on their relevance to sepsis, acute inflammation, sepsis-related immune suppression, and sepsis-related organ failure. Reference lists were reviewed to identify additional relevant articles.
DATA EXTRACTION: Relevant data was extracted and synthesized for narrative review.
DATA SYNTHESIS: Epigenetic regulation is a key determinant of gene expression in sepsis. At the onset of infection, host-pathogen interactions often result in epigenetic alterations to host cells that favor pathogen survival. In parallel, the host inflammatory response is characterized by epigenetic modifications in key regulatory genes, including tumor necrosis factor and interleukin-1β. In human sepsis patients, multiple epigenetic modifying enzymes show differential expression in early sepsis, suggesting a role for epigenetics in coordinating the response to infection. In the later stages of sepsis, epigenetic modifications accompany endotoxin tolerance and the immune-suppressed state. In animal models, treatment with epigenetic modifiers can mitigate the effects of sepsis and improve survival as well as reverse sepsis-associated organ injury.
CONCLUSIONS: Epigenetic modifications are associated with key phases of sepsis, from the host-pathogen interaction, to acute inflammation, to immune suppression. Epigenetic markers show promise in the diagnosis and prognosis of sepsis and epigenetic modifying agents show promise as therapeutic tools in animal models of sepsis. Human studies in the area of epigenetics are sorely lacking and should be a priority for sepsis researchers.
参考来源
- Binnie A, Tsang JLY, Hu P, et al. Epigenetics of Sepsis. Crit Care Med. 2020. PMID: 32167492. doi:10.1097/CCM.0000000000004247
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。